Acute kidney injury in late pregnancy in developing countries, Ren Fail, vol.32, pp.309-313, 2010. ,
Risk factors for maternal morbidity, Am J Obstet Gynecol, vol.182, pp.307-312, 2000. ,
Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, Pselectin, NGAL) at 11 1 0 to 13 1 6 weeks in the prediction of late (. 34 weeks) pre-eclampsia, Prenat Diagn, vol.31, pp.1141-1146, 2011. ,
Is pregnancy-related acute renal failure a disappearing clinical entity?, Ren Fail, vol.18, pp.575-584, 1996. ,
Acute renal failure in pregnancy in a developing country: Twenty years of experience, Ren Fail, vol.28, pp.309-313, 2006. ,
Decreasing incidence of renal cortical necrosis in patients with acute renal failure in developing countries: A single-centre experience of 22 years from Eastern India, Nephrol Dial Transplant, vol.22, pp.1213-1217, 2007. ,
Spectrum of renal cortical necrosis in acute renal failure in eastern India, Postgrad Med J, vol.71, pp.208-210, 1995. ,
Acute renal failure in pregnancy, Kidney Int, vol.18, pp.179-191, 1980. ,
Acute renal failure of obstetric origin, Obstet Gynecol, vol.48, pp.642-646, 1976. ,
Pregnancy-related acute renal failure in eastern India, Int J Gynaecol Obstet, vol.111, pp.213-216, 2010. ,
Pre-eclampsia, Lancet, vol.365, pp.785-799, 2005. ,
Morphometric analysis of pre-eclampsia in women biopsied in pregnancy and post-partum, Kidney Int, vol.34, pp.704-711, 1988. ,
Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit, Am J Obstet Gynecol, vol.186, pp.253-256, 2002. ,
, Nat Med, vol.12, pp.642-649, 2006.
CPEP Study Group: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med, vol.355, pp.992-1005, 2006. ,
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy, Am J Obstet Gynecol, vol.197, pp.28-29, 2007. ,
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia, J Biol Chem, vol.272, pp.23659-23667, 1997. ,
Effects of hypoxia-inducible factor1alpha overexpression in pregnant mice: Possible implications for preeclampsia and intrauterine growth restriction, Am J Pathol, vol.177, pp.2950-2962, 2010. ,
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction, J Exp Med, vol.203, pp.2165-2175, 2006. ,
Decidual NK cells regulate key developmental processes at the human fetal-maternal interface, Nat Med, vol.12, pp.1065-1074, 2006. ,
Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor, J Clin Invest, vol.103, pp.945-952, 1999. ,
Oxidative stress and preeclampsia: Rationale for antioxidant clinical trials, Hypertension, vol.44, pp.374-380, 2004. ,
Thrombotic microangiopathy after kidney transplantation, Am J Transplant, vol.10, pp.1517-1523, 2010. ,
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-867, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00512540
Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?, Nat Clin Pract Nephrol, vol.3, pp.679-687, 2007. ,
Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.115, pp.1500-1511, 2010. ,
Neurological involvement in a child with atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.25, pp.2539-2542, 2010. ,
Eculizumab in severe Shiga-toxinassociated HUS, N Engl J Med, vol.364, pp.2561-2563, 2011. ,
HUS Investigation Team: Epidemic profile of Shiga-toxin-producing Escherichia coli O104: H4 outbreak in Germany, N Engl J Med, vol.365, pp.1771-1780, 2011. ,
Lämmle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome, N Engl J Med, vol.339, pp.1578-1584, 1998. ,
Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-1687, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01793663
Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes, Semin Thromb Hemost, vol.36, pp.641-652, 2010. ,
Frémeaux-Bacchi V: Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-2187, 2010. ,
Frémeaux-Bacchi V: Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome, Blood, vol.112, pp.4542-4545, 2008. ,
Frémeaux-Bacchi V: Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation, Am J Transplant, vol.8, pp.1694-1701, 2008. ,
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis, J Immunol, vol.187, pp.172-180, 2011. ,
,
Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, vol.358, pp.1129-1136, 2008. ,
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases, Blood, vol.106, pp.1932-1937, 2005. ,
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura, Blood, vol.118, pp.1746-1753, 2011. ,
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases, Blood, vol.98, pp.1765-1772, 2001. ,
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010. ,
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients, Blood, vol.102, pp.60-68, 2003. ,
Changes in health and disease of the metalloprotease that cleaves von Willebrand factor, Blood, vol.98, pp.2730-2735, 2001. ,
Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura, J Obstet Gynaecol Can, vol.32, pp.1167-1171, 2010. ,
Pregnancy outcomes after maternal exposure to rituximab, Blood, vol.117, pp.1499-1506, 2011. ,
, Safety of rituximab therapy during twins' pregnancy. Rheumatology, vol.50, pp.806-808, 2011.
Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, Transfusion, vol.44, pp.1149-1158, 2004. ,
Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies, Am J Hematol, vol.51, pp.1-6, 1996. ,
ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy, Br J Haematol, vol.153, pp.277-279, 2011. ,
Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura, Blood Coagul Fibrinolysis, vol.17, pp.459-463, 2006. ,
Eculizumab (Alexion), Curr Opin Investig Drugs, vol.3, pp.1017-1023, 2002. ,
Inhibiting the C5-C5a receptor axis, Mol Immunol, vol.48, pp.1631-1642, 2011. ,
Eculizumab: A review of its use in paroxysmal nocturnal haemoglobinuria, Drugs, vol.71, pp.2327-2345, 2011. ,
Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome, Am J Transplant, vol.9, pp.2644-2645, 2009. ,
Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation, Am J Kidney Dis, vol.55, pp.708-711, 2010. ,
Eculizumab for congenital atypical hemolytic-uremic syndrome, N Engl J Med, vol.360, pp.544-546, 2009. ,
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation, Transplantation, vol.89, pp.903-904, 2010. ,
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.4, pp.1312-1316, 2009. ,
Eculizumab for atypical hemolytic-uremic syndrome, N Engl J Med, vol.360, pp.542-544, 2009. ,
Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab, Leuk Res, vol.33, pp.4-5, 2009. ,
Pregnancy in PNH: Another eculizumab baby, Br J Haematol, vol.150, pp.707-708, 2010. ,
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab, Br J Haematol, vol.149, pp.446-450, 2010. ,
Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure, Ren Fail, vol.26, pp.557-562, 2004. ,
HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: Onset at , or 528.0 weeks' gestation, Am J Obstet Gynecol, vol.183, pp.1475-1479, 2000. ,
The HELLP syndrome, a prospective study, Ren Fail, vol.23, pp.705-713, 2001. ,
Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome), Am J Obstet Gynecol, vol.169, pp.1000-1006, 1993. ,
Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989-1999), Ren Fail, vol.22, pp.319-327, 2000. ,
Pathogenesis of acute renal failure associated with the HELLP syndrome: A case report and review of the literature, Eur J Obstet Gynecol Reprod Biol, vol.108, pp.99-102, 2003. ,
Hepatic histopathologic condition does not correlate with laboratory abnormalities in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), Am J Obstet Gynecol, vol.167, pp.1538-1543, 1992. ,
Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A double-blind, placebo-controlled, randomized clinical trial, Am J Obstet Gynecol, vol.198, pp.283-284, 2008. ,
Plasmapheresis in the management of HELLP syndrome, J Obstet Gynaecol, vol.18, pp.377-379, 1998. ,
Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort, PLoS Med, vol.8, p.1001013, 2011. ,
Targeted inhibition of complement activation prevents features of preeclampsia in mice, Kidney Int, vol.79, pp.331-339, 2011. ,
Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury, Blood, vol.110, pp.2423-2431, 2007. ,
Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies, Am J Obstet Gynecol, vol.196, pp.167-168, 2007. ,